Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

NCT05204368 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

780

Enrollment

INDUSTRY

Sponsor class

Conditions

Complicated Urinary Tract Infection Including Acute Pyelonephritis

Interventions

DRUG: Combination of Imipenem/Cilastatin and XNW4107
DRUG: Meropenem

Sponsor

Evopoint Biosciences Inc.